Johnson F L, Mentzer W C, Kalinyak K A, Sullivan K M, Abboud M R
University of Chicago, Illinois.
Am J Pediatr Hematol Oncol. 1994 Feb;16(1):22-6.
As of June 1992, five patients with sickle cell disease had been treated by matched sibling bone marrow transplantation in the United States.
Three patients underwent transplantations for complications related to sickle cell disease, two with previous cerebrovascular accidents (CVAs) and one who had had multiple severe vasoocclusive crises. Two patients had other indications for allogeneic bone marrow transplantation: one had acute myeloid leukemia and the other had Morquio's disease. The patients' ages ranged from 3 to 10 years, and four were girls. Ages of the donors ranged from 4 to 13 years; four of the donors were boys and three carried the sickle cell trait. For four patients, the preparative regimen consisted of busulfan and cyclophosphamide given either alone or combined with antithymocyte globulin (ATG). The patient with leukemia was prepared with cyclophosphamide and total body irradiation (TBI). The regimens for prophylaxis of graft-versus-host disease (GVHD) included various combinations of cyclosporine A, methotrexate, and prednisone.
The patient with Morquio's disease failed to engraft but underwent a successful retransplantation from the same donor. All patients eventually demonstrated donor engraftment and the donor's hemoglobin electrophoretic pattern posttransplant. Two patients had moderately severe GVHD of the skin and gastrointestinal tract, which resolved with prednisone therapy. One of these patients developed transient chronic GVHD involving the skin. Other acute complications included mild venoocclusive disease of the liver, central line infection with bacteremias, uterine hemorrhage in one patient, and pseudomonas sepsis in another.
Both patients who underwent transplantation after CVAs have experienced subsequent neurological events. However, with a median follow-up of 16 months (range 8 months to 9.3 years), all patients are surviving in good to excellent clinical condition and appear to have benefitted from treatment by bone marrow transplantation.
截至1992年6月,在美国已有5名镰状细胞病患者接受了同胞匹配的骨髓移植治疗。
3名患者因镰状细胞病相关并发症接受移植,其中2例曾有脑血管意外(CVA),1例有多次严重血管闭塞性危机。另外2例患者有接受异基因骨髓移植的其他指征:1例患有急性髓系白血病,另1例患有黏多糖贮积症Ⅳ型。患者年龄在3至10岁之间,4例为女孩。供者年龄在4至13岁之间;4名供者为男孩,3名携带镰状细胞性状。4例患者的预处理方案为单用白消安和环磷酰胺,或两者联合抗胸腺细胞球蛋白(ATG)。白血病患者采用环磷酰胺和全身照射(TBI)进行预处理。预防移植物抗宿主病(GVHD)的方案包括环孢素A、甲氨蝶呤和泼尼松的各种组合。
黏多糖贮积症Ⅳ型患者移植未成功,但接受了来自同一供者的成功再次移植。所有患者最终均显示供者植入,且移植后呈现供者血红蛋白电泳图谱。2例患者出现皮肤和胃肠道中度严重的GVHD,经泼尼松治疗后缓解。其中1例患者发生了累及皮肤的短暂慢性GVHD。其他急性并发症包括轻度肝静脉闭塞病、中心静脉导管感染伴菌血症、1例患者子宫出血以及另1例患者假单胞菌败血症。
2例在CVA后接受移植的患者随后均出现了神经系统事件。然而,中位随访时间为16个月(范围8个月至9.3年),所有患者均存活,临床状况良好至极佳,且似乎从骨髓移植治疗中获益。